A new approach to protect against Lyme disease by targeting both the tick and the bacteria
Multivalent Tick-Microbe targeted Lyme disease vaccines
This project is creating a new type of vaccine to protect people from Lyme disease by focusing on both the ticks that carry the disease and the bacteria that cause it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Maryland, College Park NIH-funded |
| Lab location | 1 site (College Park, United States) |
| Project ID | NIH-11105903 on NIH RePORTER |
What this research studies
Lyme disease is a common tick-borne infection that affects many people each year, and current treatments don't always prevent long-term symptoms. This work aims to develop a novel vaccine that combines protective elements from both the Lyme disease bacteria and the ticks that spread it. By targeting both the pathogen and its carrier, we hope to create a more effective way to prevent infection. This vaccine uses a well-established viral system to deliver these protective components, offering a new strategy against this challenging disease.
Who could benefit from this research
Good fit: This research is ultimately intended for individuals at risk of Lyme disease, particularly those living in areas where tick exposure is common.
Not a fit: Patients who have already developed chronic Lyme disease or post-treatment Lyme disease syndrome may not directly benefit from this preventative vaccine.
Why it matters
Potential benefit: If successful, this vaccine could offer a new and more effective way to prevent Lyme disease, potentially reducing the number of new cases and the risk of chronic symptoms.
How similar studies have performed: While previous efforts have aimed at Lyme disease prevention, this approach of combining tick and microbe antigens in a multivalent vaccine is a novel strategy.
Where this research is happening
College Park, United States
- Univ of Maryland, College Park — College Park, United States (Active)
Researchers
- Principal investigator: Pal, Utpal — Univ of Maryland, College Park
- Study coordinator: Pal, Utpal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.